School of Stomatology, China Medical University, Shenyang, China.
Department of Clinical Medicine, China Medical University, Shenyang, China.
Int J Cancer. 2025 Jan 15;156(2):262-273. doi: 10.1002/ijc.35157. Epub 2024 Sep 15.
Leukemia inhibitory factor receptor (LIFR), in complex with glycoprotein 130 (gp130) as the receptor for leukemia inhibitory factor (LIF), can bind to a variety of cytokines and subsequently activate a variety of signaling pathways, including Janus kinase/signal transducer and activator of transcription 3. LIF, the most multifunctional cytokines of the interleukin-6 family acts as both a growth factor and a growth inhibitor in different types of tumors. LIF/LIFR signaling regulates a broad array of tumor-related processes including proliferation, apoptosis, migration, invasion. However, due to the activation of different signaling pathways, opposite regulatory effects are observed in certain tumor cells. Therefore, the role of LIFR in human cancers varies across different tumor and tissue, despite their recognized value in tumor treatment and prognosis observation is affirmed. Given its aberrant expression in numerous tumor cells and crucial regulatory function in tumorigenesis and progression, LIFR is considered as a promising targeted therapeutic agent. This review provides an overview of LIFR's initiating signaling pathway function as a cytokine receptor and summarize the current literature on the role of LIFR in cancer and its possible use in therapy.
白血病抑制因子受体 (LIFR) 与糖蛋白 130 (gp130) 形成复合物作为白血病抑制因子 (LIF) 的受体，可与多种细胞因子结合，并随后激活多种信号通路，包括 Janus 激酶/信号转导和转录激活因子 3。LIF 是白细胞介素 6 家族中最具多功能性的细胞因子，在不同类型的肿瘤中既作为生长因子又作为生长抑制剂发挥作用。LIF/LIFR 信号通路调节广泛的与肿瘤相关的过程，包括增殖、凋亡、迁移和侵袭。然而，由于不同信号通路的激活，在某些肿瘤细胞中观察到相反的调节作用。因此，尽管 LIFR 在肿瘤治疗和预后观察方面具有公认的价值，但它在人类癌症中的作用因肿瘤和组织的不同而有所不同。鉴于其在许多肿瘤细胞中的异常表达及其在肿瘤发生和进展中的关键调节功能，LIFR 被认为是一种有前途的靶向治疗药物。本综述概述了 LIFR 作为细胞因子受体的起始信号通路功能，并总结了目前关于 LIFR 在癌症中的作用及其在治疗中的可能应用的文献。
